Home
About
Platform Technologies
Pancreatic cancer
Oral cavity cancer
Type 1 diabetes
Breast cancer
HIV
Medical aesthetics
News
Careers
Contact
Connect with us

Precision delivery changes everything

Continuity Biosciences is built on a simple idea:

Therapeutic potential should be amplified through precision delivery.

By combining advanced engineering with deep biological insights, we develop adaptive delivery platforms designed to help promising therapies reach where they are needed most. By bringing medtech and biotech together, we aim to achieve what neither can do alone.
1
Platforms

Platforms built to expand therapeutic reach

Multiple platforms. One mission: helping therapies reach where they can have the greatest impact.
Rather than focusing on a single drug, disease, or modality, we develop adaptive precision delivery technologies designed to support a wide range of therapeutic applications. Our platforms are designed to help interventions reach their intended targets more precisely and perform more effectively.
01
Pancreatic cancer
Our implantable iontophoretic system uses mild electrical current to deliver chemotherapy directly into tumor tissue, with the intention of maximizing impact at the source while minimizing systemic exposure.
02
Oral cavity cancer
Our iontophoretic system delivers chemotherapy directly into oral tumors using mild electrical current during a brief and minimally invasive outpatient procedure.
03
TYPE 1 DIABETES
NICHE, our subcutaneously implantable combination product, is designed to house insulin-producing cells in the body and provide a locally immuno-protected environment that supports their extended survival.
04
hiv
NanoDDI is a subdermal implant that is designed to deliver sustained therapy over months or years, reducing daily treatment burden and supporting long-lasting effects.
05
breast cancer
NDES, our nanofluidic drug-eluting seed, is intended to release therapy directly within the tumor, maintaining a sustained, localized therapeutic presence.
06
medical aesthetics
Our patch technology goes beyond surface-level aesthetics, using intradermal precision to deliver ingredients beneath the surface for a more targeted approach to skincare.
01
Pancreatic cancer
Our implantable iontophoretic system uses mild electrical current to deliver chemotherapy directly into tumor tissue, with the intention of maximizing impact at the source while minimizing systemic exposure.
02
Oral cavity cancer
Our iontophoretic system delivers chemotherapy directly into oral tumors using mild electrical current during a brief and minimally invasive outpatient procedure.
03
TYPE 1 DIABETES
NICHE, our subcutaneously implantable combination product, is designed to house insulin-producing cells in the body and provide a locally immuno-protected environment that supports their extended survival.
04
hiv
NanoDDI is a subdermal implant that is designed to deliver sustained therapy over months or years, reducing daily treatment burden and supporting long-lasting effects.
05
breast cancer
NDES, our nanofluidic drug-eluting seed, is intended to release therapy directly within the tumor, maintaining a sustained, localized therapeutic presence.
06
medical aesthetics
Our patch technology goes beyond surface-level aesthetics, using intradermal precision to deliver ingredients beneath the surface for a more targeted approach to skincare.
01
Pancreatic cancer
Our implantable iontophoretic system uses mild electrical current to deliver chemotherapy directly into tumor tissue, with the intention of maximizing impact at the source while minimizing systemic exposure.
02
Oral cavity cancer
Our iontophoretic system delivers chemotherapy directly into oral tumors using mild electrical current during a brief and minimally invasive outpatient procedure.
03
TYPE 1 DIABETES
NICHE, our subcutaneously implantable combination product, is designed to house insulin-producing cells in the body and provide a locally immuno-protected environment that supports their extended survival.
04
hiv
NanoDDI is a subdermal implant that is designed to deliver sustained therapy over months or years, reducing daily treatment burden and supporting long-lasting effects.
05
breast cancer
NDES, our nanofluidic drug-eluting seed, is intended to release therapy directly within the tumor, maintaining a sustained, localized therapeutic presence.
06
medical aesthetics
Our patch technology goes beyond surface-level aesthetics, using intradermal precision to deliver ingredients beneath the surface for a more targeted approach to skincare.
01
Pancreatic cancer
Our implantable iontophoretic system uses mild electrical current to deliver chemotherapy directly into tumor tissue, with the intention of maximizing impact at the source while minimizing systemic exposure.
02
Oral cavity cancer
Our iontophoretic system delivers chemotherapy directly into oral tumors using mild electrical current during a brief and minimally invasive outpatient procedure.
03
TYPE 1 DIABETES
NICHE, our subcutaneously implantable combination product, is designed to house insulin-producing cells in the body and provide a locally immuno-protected environment that supports their extended survival.
04
hiv
NanoDDI is a subdermal implant that is designed to deliver sustained therapy over months or years, reducing daily treatment burden and supporting long-lasting effects.
05
breast cancer
NDES, our nanofluidic drug-eluting seed, is intended to release therapy directly within the tumor, maintaining a sustained, localized therapeutic presence.
06
medical aesthetics
Our patch technology goes beyond surface-level aesthetics, using intradermal precision to deliver ingredients beneath the surface for a more targeted approach to skincare.
2
research & press
135
publications
80
patents
research
Read our press
3
people

Experience behind every breakthrough

The team behind Continuity Biosciences brings together the expertise needed to move bold delivery technologies from concept to real-world impact.
Meet the team
Robert Whitehead
Co-Founder & Executive Chair
Robert Whitehead
Co-Founder & Executive Chair
Serial biopharma entrepreneur with multiple successful exits, including Slate (sold to GTCR) and Sprout Pharmaceuticals (sold to Valeant). Co-founder and current board member of Sprout — reacquired in 2018 — and named in 2026 to TIME's list of the 10 most influential health and life sciences companies, Robert has a track record of building and scaling high-impact, life science companies.
Ramakrishna Venugopalan, PhD, MBA
Co-Founder & Chief Executive Officer
Ramakrishna Venugopalan, PhD, MBA
Co-Founder & Chief Executive Officer
Combination product and drug delivery executive with proven AbbVie experience advancing globally impactful therapies, including Skyrizi®, Ozurdex®, and Vyalve®.
Alessandro Grattoni, PhD
Co-Founder & Chief Technology Advisor
Alessandro Grattoni, PhD
Co-Founder & Chief Technology Advisor
Nanomedicine pioneer and Chair of the Center for BioNanoengineering at Houston Methodist Hospital, with deep expertise in implantable and nanofluidic drug delivery technologies and cell therapeutics.
Contact us

Is your next breakthrough built to deliver?

As we continue to advance our platforms, we welcome conversation with partners and collaborators who share our excitement about what becomes possible when breakthrough biology is paired with better delivery.
Connect with us